Timely Diagnosis and Treatment Shortens the Time to Resolution of Coronavirus Disease (COVID-19) Pneumonia and Lowers the Highest and Last CT Scores From Sequential Chest CT

Huang, Guoquan; Gong, Tao; Wang, Guangbin; Wang, Jianwen; Guo, Xinfu; Erpeng, Cai; Liu, Shirong; Li, Xiaohu; Yu, Yongqiang; Lin, Liangjie

doi:10.2214/ajr.20.23078

Cited by 97 publications

(110 citation statements)

References 7 publications

Supporting

Mentioning

103

Contrasting

Unclassified

Order By: Relevance

“…Whenever available, CT images were centrally reviewed by two senior radiologists with consensus qualitative and semiquantitative assessment. In accordance with previous reports on COVID-19 imaging [7,8], the following patterns were sought: ground-glass opacity, crazy paving (ground-glass opacity associated with interlobular septal thickening [9]), focal consolidation, and linear consolidation. To be included in the COVID-19 population, patients with negative or not available RNA test had to display typical and newly acquired (i.e., not pre-existing on the previous CT scan) COVID-19-related lung lesions.…”

Section: Ct Scan Protocol and Image Interpretationmentioning

confidence: 94%

COVID-19 in breast cancer patients: a cohort at the Institut Curie hospitals in the Paris area

et al. 2020

View full text Add to dashboard Cite

Background: Cancer patients have been reported to be at higher risk of COVID-19 complications and deaths. We report the characteristics and outcome of patients diagnosed with COVID-19 during breast cancer treatment at Institut Curie hospitals (ICH, Paris area, France). Methods: An IRB-approved prospective registry was set up at ICH on March 13, 2020, for all breast cancer patients with COVID-19 symptoms or radiologic signs. Registered data included patient history, tumor characteristics and treatments, COVID-19 symptoms, radiological features, and outcome. Data extraction was done on April 25, 2020. COVID-19 patients were defined as those with either a positive RNA test or typical, newly appeared lung CT scan abnormalities. Results: Among 15,600 patients actively treated for early or metastatic breast cancer during the last 4 months at ICH, 76 patients with suspected COVID-19 infection were included in the registry and followed. Fifty-nine of these patients were diagnosed with COVID-19 based on viral RNA testing (N = 41) or typical radiologic signs: 37/59 (63%) COVID-19 patients were treated for metastatic breast cancer, and 13/59 (22%) of them were taking corticosteroids daily. Common clinical features mostly consisted of fever and/or cough, while ground-glass opacities were the most common radiologic sign at diagnosis. We found no association between prior radiation therapy fields or extent of radiation therapy sequelae and extent of COVID-19 lung lesions. Twenty-eight of these 59 patients (47%) were hospitalized, and 6 (10%) were transferred to an intensive care unit. At the time of analysis, 45/59 (76%) patients were recovering or had been cured, 10/59 (17%) were still followed, and 4/59 (7%) had died from COVID-19. All 4 patients who died had significant non-cancer comorbidities. In univariate analysis, hypertension and age (> 70) were the two factors associated with a higher risk of intensive care unit admission and/or death.

show abstract

Section: Ct Scan Protocol and Image Interpretationmentioning

confidence: 94%

COVID-19 in breast cancer patients: a cohort at the Institut Curie hospitals in the Paris area

et al. 2020

View full text Add to dashboard Cite

show abstract

“…The mean or median age of patients ranged from 3 to 70 years. Twelve studies were from Wuhan, China (3,23,25,26,29,36,49,51,61,71,75,77). Correlations were observed between disease severity and the proportion of patients with comorbidities (Spearman's ρ = 0.53; p = 0.003) and between disease severity and the proportion of elderly patients I n P r e s s (Spearman's ρ = 0.52; p = 0.01).…”

Section: Study Characteristicsmentioning

confidence: 99%

Diagnostic Performance of CT and Reverse Transcriptase Polymerase Chain Reaction for Coronavirus Disease 2019: A Meta-Analysis

2020

View full text Add to dashboard Cite

statement: Chest computed tomography scans for the primary screening or diagnosis of coronavirus disease 2019 would not be beneficial in a low-prevalence region due to the substantial rate of false-positives.This copy is for personal use only. To order printed copies, contact reprints@rsna.org I n P r e s s Key Results• The pooled sensitivity and specificity were 94% (95% CI: 91%, 96%) and 37% (95% CI: 26%, 50%), respectively, for chest CT. The pooled sensitivity of reverse transcriptasepolymerase chain reaction (RT-PCR) was 89% (95% CI: 81%, 94%).• In low-prevalence (<10%) countries, the positive predictive value of RT-PCR (range: 47.3%, 84.3%) was more than ten times higher than that of CT scans (range: 1.5%, 8.3%).The negative predictive value of both methods ranged from 99.0% to 99.9%. AbbreviationsCI = confidence interval, COVID-19 = coronavirus disease 2019, NPV = negative predictive value, ORF = open reading frame, PPV = positive predictive value, PRISMA = Preferred Reporting Items for Systematic Reviews and Meta-analyses, QUADAS-2 = Quality Assessment of Diagnostic Accuracy Studies-2, RT-PCR = reverse transcriptase-polymerase chain reaction, SARS-CoV-2 = severe acute respiratory syndrome coronavirus 2, WHO = World Health Organization I n P r e s s Abstract Background: Recent studies have suggested that chest computed tomography (CT) scans could be used as a primary screening or diagnostic tool for coronavirus disease 2019 (COVID-19) in epidemic areas.Purpose: To perform a meta-analysis to evaluate diagnostic performance measures, including predictive values, of chest CT and initial reverse transcriptase-polymerase chain reaction (RT-PCR). studies on COVID-19 that reported the sensitivity and/or specificity of CT scans and/or RT-PCR assays. The pooled sensitivity and specificity were estimated by using random-effects models. The actual prevalence (i.e., the proportion of confirmed patients among those tested) in eight countries was obtained from web sources, and the predictive values were calculated. Meta-regression was performed to reveal the effect of potential explanatory factors on the diagnostic performance measures. Results:The pooled sensitivity was 94% (95% CI: 91%, 96%; I 2 =95%) for chest CT and 89% (95% CI: 81%, 94%; I 2 =90%) for RT-PCR. The pooled specificity was 37% (95% CI: 26%, 50%; I 2 =83%) for chest CT. The prevalence of COVID-19 outside China ranged from 1.0% to 22.9%. For chest CT scans, the positive predictive value (PPV) ranged from 1.5% to 30.7%, and the negative predictive value (NPV) ranged from 95.4% to 99.8%. For RT-PCR, the PPV ranged from 47.3% to 96.4%, while the NPV ranged from 96.8% to 99.9%. The sensitivity of CT was affected by the distribution of disease severity, the proportion of patients with comorbidities, and the proportion of asymptomatic patients (all p < 0.05). The sensitivity of RT-PCR was negatively associated with the proportion of elderly patients (p = 0.01). Conclusion:Outside of China where there is a low-prevalence of COVID-19 (1-22.9%), chest CT screening...

show abstract

“…previous reports on COVID-19 imaging [14,15], the following patterns were sought: ground-glass opacity, crazy paving (ground glass opacity associated with interlobular septal thickening [16]), focal consolidation and linear consolidation. To be included in the COVID-19 population, patients with negative or not available RNA test had to display typical and newly acquired (i.e.…”

Section: Registrymentioning

confidence: 99%

COVID-19 in breast cancer patients: a cohort at the Institut Curie hospitals in the Paris area

Vuagnat

Frélaut

Ramtohul

et al. 2020

Preprint

View full text Add to dashboard Cite

Background: Cancer patients have been reported to be at higher risk of COVID-19 complications and deaths. We report the characteristics and outcome of patients diagnosed with COVID-19 during breast cancer treatment at Institut Curie hospitals (ICH, Paris area, France).Methods: An IRB-approved prospective registry was set up at ICH on March 13 th , 2020 for all breast cancer patients with COVID-19 symptoms or radiologic signs. Registered data included patient history, tumor characteristics and treatments, COVID-19 symptoms, radiological features and outcome. Data extraction was done on April 25 th , 2020. COVID-19 patients were defined as those with either a positive RNA test or typical, newly appeared lung CT-scan abnormalities.Results: Among 15,600 patients actively treated for early or metastatic breast cancer during the last 4 months at ICH, 76 patients with suspected COVID-19 infection were included in the registry and followed.Fifty-nine of these patients were diagnosed with COVID-19 based on viral RNA testing (N=41) or typical radiologic signs: 37/59 (63%) COVID-19 patients were treated for metastatic breast cancer, and 13/59 (22%) of them were taking corticosteroids daily. Common clinical features mostly consisted of fever and/or cough, while ground-glass opacities were the most common radiologic sign at diagnosis. We found no association between prior radiation therapy fields or extent of radiation therapy sequelae and extent of COVID-19 lung lesions. Twenty-eight of these 59 patients (47%) were hospitalized and 6 (10%) were transferred to an intensive care unit. At the time of analysis, 45/59 (76%) patients were recovering or had been cured, 10/59 (17%) were still followed and 4/59 (7%) had died from COVID-19. All 4 patients who died had significant non-cancer comorbidities. In univariate analysis, hypertension and age (>70) were the two factors associated with a higher risk of intensive care unit admission and/or death. Conclusions:This prospective registry analysis suggests that the COVID-19 mortality rate in breast cancer patients depends more on comorbidities than prior radiation therapy or current anti-cancer treatment. Special attention must be paid to comorbidities when estimating the risk of severe COVID-19 in breast cancer patients.All rights reserved. No reuse allowed without permission.(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

show abstract

Timely Diagnosis and Treatment Shortens the Time to Resolution of Coronavirus Disease (COVID-19) Pneumonia and Lowers the Highest and Last CT Scores From Sequential Chest CT

Cited by 97 publications

References 7 publications

COVID-19 in breast cancer patients: a cohort at the Institut Curie hospitals in the Paris area

COVID-19 in breast cancer patients: a cohort at the Institut Curie hospitals in the Paris area

Diagnostic Performance of CT and Reverse Transcriptase Polymerase Chain Reaction for Coronavirus Disease 2019: A Meta-Analysis

COVID-19 in breast cancer patients: a cohort at the Institut Curie hospitals in the Paris area

Contact Info

Product

Resources

About